This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
projects:workgroups:transfusion [2019/12/02 14:12] cgreich |
projects:workgroups:transfusion [2019/12/13 02:38] cgreich |
||
---|---|---|---|
Line 7: | Line 7: | ||
Transfusions are special treatments which are currently in active research by the FDA BEST and the [[https://www.nhlbi.nih.gov/science/recipient-epidemiology-and-donor-evaluation-study-reds-program|REDS-IV]] program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap. | Transfusions are special treatments which are currently in active research by the FDA BEST and the [[https://www.nhlbi.nih.gov/science/recipient-epidemiology-and-donor-evaluation-study-reds-program|REDS-IV]] program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap. | ||
- | * [[documentation:transfusion:Data_Source|Use Cases]] | + | * Use Cases: |
+ | |||
+ | * Effect of number of units on outcomes | ||
+ | * Effect of single donor vs pooled on outcomes | ||
+ | * Effect agency blood products are obtained from (such as ARC vs NYBC) on outcomes | ||
+ | * Incidence rates of severe outcomes: TRALI, TACO, Sepsis, HTRs, PTP, thrombosis and others | ||
+ | * Fatality rates of outcomes | ||
+ | * Incidence rates of outcomes by specific blood products transfused: red blood cells, plasma, platelets, full blood | ||
+ | * Incidence rates of outcomes by blood component processing: leukocyte reduction, irradiation, pathogen-reduction | ||
+ | * Incidence rates of outcomes by indication and associated procedures and other possible risk factors | ||
+ | * Incidence rates of outcomes by donor characteristics | ||
* Modelling Isues: | * Modelling Isues: | ||
Line 17: | Line 27: | ||
* monitoring: preparation, processing, mobilization, modification, quarantine, | * monitoring: preparation, processing, mobilization, modification, quarantine, | ||
* Additive, excipient and nutrient content | * Additive, excipient and nutrient content | ||
- | |||
- | donor pooling, exposure and type | ||
- | |||